Genmab — Januar 2015
-
Som skrevet tidligere så mener jeg faktisk at Genmab står lidt svagt overfor Janssen i lige præcis denne tid - for ved gennembrud med Dara i monoterapi, så sidder Janssen/Genmab på alt hvad der har værdi. Novartis kommer til at side på Arzerra plus lidt DuoBody og Seattle Genetics er med i ADC´erne mod TF og AXL,
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind

